Price (delayed)
$25.62
Market cap
$1.78B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.44
Enterprise value
$1.5B
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
There are no recent dividends present for AKRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.